{
    "prompt": "Please provide each treatment as a json format with the following JSON schema.\n    {\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\":\n            \"Link to FDA-approved Label\": \n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0029515\nAge: 38\nGender: Female\nSample ID: P-0029515-T01-IM6\nGene Panel: IMPACT468\nCancer Type: Invasive Breast Carcinoma\nSample Type: Metastasis\nTumor Purity: 40.0%\n=============\nDNA Variants:\nNUP93 c.43C>T (p.Q15*) - in 7.00% of 421 reads\nNUP93 c.2369G>A (p.R790H) - in 14.00% of 525 reads\nPIK3CA c.3140A>G (p.H1047R) - in 18.00% of 483 reads\nTEK c.1445T>C (p.L482P) - in 15.00% of 662 reads\nCNA Data:\nCCND1 - High Level Amplification\nFGFR1 - High Level Amplification\nWHSC1L1 - High Level Amplification\nPTP4A1 - High Level Amplification\nFGF4 - High Level Amplification\nFGF3 - High Level Amplification\nFGF19 - High Level Amplification\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Treatment 1\": {\n    \"Disease Name\": \"Invasive Breast Carcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Alpelisib\",\n    \"Prior Treatment or Resistance Status\": \"Postmenopausal women, and men, with HR+, HER2-negative, PIK3CA mutated, advanced or metastatic breast cancer following progression on or after endocrine-based therapy\",\n    \"Genomic Features\": \"Somatic variant in gene PIK3CA (c.3140A>G, p.H1047R)\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212526s001lbl.pdf\"\n  },\n  \"Treatment 2\": {\n    \"Disease Name\": \"Invasive Breast Carcinoma\",\n    \"Disease Phase or Condition\": \"Metastatic\",\n    \"Drug Name\": \"Capivasertib + Fulvestrant\",\n    \"Prior Treatment or Resistance Status\": \"Progression on or after endocrine-based therapy in HR+, HER2-negative breast cancer with PIK3CA/AKT1/PTEN alterations\",\n    \"Genomic Features\": \"Somatic variant in gene PIK3CA (c.3140A>G, p.H1047R)\",\n    \"Link to FDA-approved Label\": \"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/218197s000lbl.pdf\"\n  }\n}"
}